Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
36 studies found for:    mononucleosis
Show Display Options
RSS Create an RSS feed from your search for:
mononucleosis
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Acupuncture for Infectious Mononucleosis Trial
Condition: Infectious Mononucleosis
Interventions: Procedure: traditional Chinese acupuncture;   Other: standard medical care
2 Completed Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
Condition: Infectious Mononucleosis
Interventions: Drug: Valomaciclovir;   Drug: placebo
3 Completed Controlled Trial of Valacyclovir in Infectious Mononucleosis
Condition: Infectious Mononucleosis
Intervention: Drug: valacyclovir
4 Completed Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals’ EBV (Epstein Barr Virus) Vaccine (268664).
Condition: Epstein Barr Virus (EBV) Infection
Intervention: Biological: EBV vaccine (268664)
5 Recruiting Genetic Studies of Chronic Active Epstein-Barr Disease
Condition: Epstein-Barr Virus Infections
Intervention:
6 Completed Genetic Studies of X-linked Lymphoproliferative Disease
Conditions: X-Linked Lymphoproliferative Disease;   Lymphoproliferative Disease;   Genetic Diseases, X-Linked
Intervention:
7 Recruiting A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Conditions: Congenital Cytomegalovirus Infection;   Maternal Cytomegalovirus Infection
Intervention: Drug: CMV hyperimmune globulin
8 Completed Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma
Condition: Indolent Non-Hodgkin's Lymphoma
Intervention:
9 Not yet recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific CTLs
10 Terminated Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease
Conditions: Hodgkin Disease;   Non-Hodgkins Lymphoma
Intervention: Drug: Infusion of EBV Specific Cytotoxic T-Lymphocytes
11 Completed
Has Results
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
Condition: Cytomegalovirus Infections
Intervention: Biological: ALVAC-CMV (vCP260)
12 Unknown  HIV Indicator Diseases Across Europe Study
Condition: HIV
Intervention:
13 Completed Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL
Conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma;   Epstein-Barr Virus-Related Non-Hodgkin Lymphoma;   EBV Positive Plasma Cell Neoplasm
Intervention: Genetic: Injection of EBV Specific CTLs
14 Recruiting Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Biological: Antigen Escalation Stage;   Biological: Dose escalation study of T cells
15 Completed T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
Condition: Head and Neck Cancer
Intervention: Biological: autologous EBV specific CTLs
16 Recruiting Specific Cytotoxic T-Lymphocytes, EBV-positive Lymphoma, GRALE
Conditions: Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Lymphoproliferative Disease;   Lymphoma
Interventions: Biological: LMP, BARF1 & EBNA1 specific CTLs: A;   Biological: LMP, BARF1 & EBNA1 specific CTLs : B
17 Completed LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Condition: Nasopharyngeal Carcinoma
Intervention: Genetic: Genetically modified CTLs
18 Terminated Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
Conditions: Hodgkins Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES;   Genetic: LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
19 Terminated Vaccination With Tetanus and KLH to Assess Immune Responses.
Condition: Cancer
Interventions: Biological: Intracel KLH Vaccine;   Biological: Biosyn KLH;   Drug: Montanide ISA51;   Biological: Tetanus toxoid
20 Not yet recruiting MOST CLOSELY MATCHED 3RD PARTY RAPIDLY GENERATED LMP, BARF1 and EBNA1 SPECIFIC CTL, EBV-POSITIVE LYMPHOMA
Conditions: Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
Intervention: Biological: MABEL CTLs

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years